Skip to main content

Table 2 Baseline characteristics in the patients with complete clinical and radiographic data divided by: A) radiological progression or not during the first 24 months (increase in total SHS score > 5 points) and B) hand bone loss or not during the first 12 months (DXR-BMD change rate ≥ 2.5 mg/cm 2 /month)

From: Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial

  Radiological progression   Hand bone loss  
  YES (N = 43) NO (N = 101) p-value YES (N = 23) NO (N = 126) p-value
Symptom duration, months 6.25 (3.27) 5.98 (3.15) 0.70 5.97 (3.13) 6.70 (3.66) 0.30
T-SHS = 0,% 27.9 47.5 0.04 30.5 43.7 0.26
ES =0,% 46.5 63.4 0.04 47.8 59.5 0.36
DAS 28 5.89 (1.01) 5.60 (1.00) 0.13 5.86 (0.95) 5.66 (0.98) 0.37
ESR (mm) 49.8 (30.9) 31.57 (20.9) <0.001 46.6 (25.9) 37.1 (26.7) 0.12
CRP (mg/L) 47.7 (41.7) 27.2 (36.2) <0.001 56.9 (47.4) 30.8 (37.6) 0.004
RF pos.% 38.3 28.6 0.30 35.5 30.5 0.68
ACPA pos.% 64.0 41.4 0.60 56.5 61.4 0.65
  1. Abbreviation: T-SHS: Total van der Heijde modified Sharp score, ES: Erosion Score, DAS28: 28 joint-based disease activity score, ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, RF: Rheumatoid factor, ACPA: Anti-citrullinated protein antibody.